Publications

BibTex format

@article{Ahn:2022:10.1016/j.cllc.2022.07.008,
author = {Ahn, MJ and Kim, HR and Yang, JCH and Han, J-Y and Li, JY-C and Hochmair, MJ and Chang, G-C and Delmonte, A and Lee, KH and Campelo, RG and Gridelli, C and Spira, A and Califano, R and Griesinger, F and Ghosh, S and Felip, E and Kim, D-W and Liu, Y and Zhang, P and Popat, S and Camidge, DR},
doi = {10.1016/j.cllc.2022.07.008},
journal = {CLINICAL LUNG CANCER},
pages = {720--730},
title = {Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive<i> ALK plus </i> Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study},
url = {http://dx.doi.org/10.1016/j.cllc.2022.07.008},
volume = {23},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Ahn,MJ
AU  - Kim,HR
AU  - Yang,JCH
AU  - Han,J-Y
AU  - Li,JY-C
AU  - Hochmair,MJ
AU  - Chang,G-C
AU  - Delmonte,A
AU  - Lee,KH
AU  - Campelo,RG
AU  - Gridelli,C
AU  - Spira,A
AU  - Califano,R
AU  - Griesinger,F
AU  - Ghosh,S
AU  - Felip,E
AU  - Kim,D-W
AU  - Liu,Y
AU  - Zhang,P
AU  - Popat,S
AU  - Camidge,DR
DO  - 10.1016/j.cllc.2022.07.008
EP  - 730
PY  - 2022///
SN  - 1525-7304
SP  - 720
TI  - Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive<i> ALK plus </i> Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
T2  - CLINICAL LUNG CANCER
UR  - http://dx.doi.org/10.1016/j.cllc.2022.07.008
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000905581000019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 23
ER  -

Download

DrSanjayPopat

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)